Contents

Search

haemophilus b vaccine; HIB vaccine (HibTITER, Hiberix)

Indications: - immunization of children 2 months to 5 years of age against diseases caused by Haemophilus influenzae type b - functional asplenia - hematopoietic stem cell transplantation Contraindications: - immunosuppression? Caution: 1) do not administer IV 2) monitor for hypersensitivity, have epinephrine available 3) contains thimerosal pregnancy-category C safety in lactation ? Dosage: Primary series: - 2-6 months: - 3 separate injections of 0.5 mL given at 2 month intervals - administered at ages 2, 4, & 6 months - 1st dose can be given as early as 6 weeks of age - 7-11 months: (previously unvaccinated) 2 separate injections of 0.5 mL given at 2 month intervals - 12-14 months: (previously unvaccinated) single injection of 0.5 mL Booster: 1) all vaccinated children receive a single booster at >= 15 months of age, but not < 2 months after previous dose 2) previously unvaccinated children 15-60 months receive a single 0.5 mL injection Injection: 1) capsular oligosaccharide 10 ug & diphtheria CRM197 protein 2) 25 ug/0.5 mL dose 3) 0.5, 2.5 & 5 mL vials Pharmacokinetics: elimination: liver Adverse effects: 1) common (> 10%) - acute febrile reactions* 2) less common (1-10%) - irritation at injection site, anorexia, diarrhea, fever (up to 102.2 F), irritability, lethargy 3) uncommon (< 1%) - allergic or anaphylactic reactions, convulsions, vomiting, fever > 102.2 F 4) no serious adverse effects [4] * acetaminophen may be used for post-vaccination fever

Related

Haemophilus thimerosal; ethylmercurothiosalycilate; thiomersalate; mercurothiolate; merthiolate; merzonin; vitaseptol

General

vaccine

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Department of Veterans Affairs, VA National Formulary
  3. Centers for Disease Control and Prevention (CDC) Updated Recommendations for Use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12--15 Months MMWR June 26, 2009 / 58(24);673-674
  4. Maglione MA et al Safety of Vaccines Used for Routine Immunization of US Children: A Systematic Review. Pediatrics; published online July 1, 2014 PMID: 25086160 http://pediatrics.aappublications.org/content/early/2014/06/26/peds.2014-1079.full.pdf+html - Byington CL Vaccines: Can Transparency Increase Confidence and Reduce Hesitancy? Pediatrics; published online July 1, 2014 PMID: 25086161 http://pediatrics.aappublications.org/content/early/2014/06/26/peds.2014-1494.full.pdf+html
  5. Briere EC. Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series. MMWR Morb Mortal Wkly Rep 2016;65:418-419. http://www.cdc.gov/mmwr/volumes/65/wr/mm6516a3.htm

Component-of

acellular pertussis vaccine/diphtheria toxoid/haemophilus B vaccine/hepatitis B vaccine/poliovirus inactivated vaccine/tetanus toxoid (DtaP-HepB-IPV) diphtheria toxoid/haemophilus b vaccine diphtheria, tetanus toxoid, pertussis & haemophilus b vaccine (Tetramune, DTP-Hib) haemophilus b vaccine/hepatitis b vaccine Haemophilus B vaccine/meningococcal polysaccharide vaccine/tetanus toxoid haemophilus b vaccine/tetanus toxoid Haemophilus influenzae b/Hepatitis B vaccine (HepB-Hib)